Published in HPB (Oxford) on December 01, 2010
Developing a natural language processing application for measuring the quality of colonoscopy procedures. J Am Med Inform Assoc (2011) 1.28
Identifying primary and recurrent cancers using a SAS-based natural language processing algorithm. J Am Med Inform Assoc (2012) 1.01
Natural language processing accurately categorizes findings from colonoscopy and pathology reports. Clin Gastroenterol Hepatol (2013) 0.98
Automated pancreatic cyst screening using natural language processing: a new tool in the early detection of pancreatic cancer. HPB (Oxford) (2014) 0.76
Knowledge Author: facilitating user-driven, domain content development to support clinical information extraction. J Biomed Semantics (2016) 0.75
Performance of a Natural Language Processing (NLP) Tool to Extract Pulmonary Function Test (PFT) Reports from Structured and Semistructured Veteran Affairs (VA) Data. EGEMS (Wash DC) (2016) 0.75
A general natural-language text processor for clinical radiology. J Am Med Inform Assoc (1995) 29.81
International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology (2006) 8.83
Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol (2008) 4.70
Identification of findings suspicious for breast cancer based on natural language processing of mammogram reports. Proc AMIA Annu Fall Symp (1997) 4.60
Automated detection of adverse events using natural language processing of discharge summaries. J Am Med Inform Assoc (2005) 3.77
Identification of suspected tuberculosis patients based on natural language processing of chest radiograph reports. Proc AMIA Annu Fall Symp (1996) 3.74
Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. Arthritis Rheum (2004) 3.21
Analysis of small cystic lesions of the pancreas. Int J Pancreatol (1995) 2.93
Practice databases and their uses in clinical research. Stat Med (1991) 2.34
A natural language processing system to extract and code concepts relating to congestive heart failure from chest radiology reports. AMIA Annu Symp Proc (2006) 1.73
Using a natural language processing system to extract and code family history data from admission reports. AMIA Annu Symp Proc (2006) 1.70
Using natural language processing to improve accuracy of automated notifiable disease reporting. AMIA Annu Symp Proc (2008) 1.69
Improving the use of clinical databases. BMJ (2002) 1.24
Intraductal papillary mucinous neoplasm--when to resect? Adv Surg (2008) 1.05
Accuracy of ICD-9-CM coding of cervical spine fractures: implications for research using administrative databases. Ann Adv Automot Med (2008) 1.03
The inaccuracy of ICD-9-CM Code 530.2 for identifying patients with Barrett's esophagus. Dis Esophagus (2008) 0.91
Using clinical databases to evaluate healthcare interventions. Int J Technol Assess Health Care (2010) 0.84
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22
A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage. Ann Surg (2014) 7.08
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology (2004) 3.27
Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol (2007) 2.87
Laparoscopic versus open left pancreatectomy: can preoperative factors indicate the safer technique? Ann Surg (2011) 2.87
Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg (2007) 2.10
Neuroendocrine tumors of the pancreas. Oncologist (2009) 1.91
A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon's contribution to long-term survival in pancreatic cancer. J Gastrointest Surg (2006) 1.89
A quantitative analysis of adverse events and "overwarning" in drug labeling. Arch Intern Med (2011) 1.88
ADESSA: A Real-Time Decision Support Service for Delivery of Semantically Coded Adverse Drug Event Data. AMIA Annu Symp Proc (2010) 1.84
A multicenter analysis of distal pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? J Am Coll Surg (2010) 1.83
Adequacy of hospital discharge summaries in documenting tests with pending results and outpatient follow-up providers. J Gen Intern Med (2009) 1.75
Fatty pancreas: a factor in postoperative pancreatic fistula. Ann Surg (2007) 1.62
Robotic distal pancreatectomy: cost effective? Surgery (2010) 1.47
Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg (2010) 1.35
CT vs MRCP: optimal classification of IPMN type and extent. J Gastrointest Surg (2007) 1.34
Does type of pancreaticojejunostomy after pancreaticoduodenectomy decrease rate of pancreatic fistula? A randomized, prospective, dual-institution trial. J Am Coll Surg (2009) 1.29
Demographic and clinical factors related to ostomy complications and quality of life in veterans with an ostomy. J Wound Ostomy Continence Nurs (2008) 1.28
The role of nuclear factor kappaB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas (2008) 1.28
Role of endoscopic ultrasound in the diagnosis of intraductal papillary mucinous neoplasms: correlation with surgical histopathology. Clin Gastroenterol Hepatol (2007) 1.26
Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg (2004) 1.25
Comparing methods for identifying pancreatic cancer patients using electronic data sources. AMIA Annu Symp Proc (2010) 1.25
Pancreatic acinar cell carcinoma: a multi-institutional study. J Gastrointest Surg (2009) 1.23
Preoperative predictors of malignancy in pancreatic intraductal papillary mucinous neoplasms. Arch Surg (2003) 1.17
Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells. Mol Cancer Ther (2005) 1.16
Preservation of replaced or accessory right hepatic artery during pancreaticoduodenectomy for adenocarcinoma: impact on margin status and survival. J Gastrointest Surg (2010) 1.12
Rodent models of alcoholic liver disease: of mice and men. Alcohol (2012) 1.11
Overcoming challenges: life with an ostomy. Am J Surg (2010) 1.08
Analysis of Ki-67 antigen expression, DNA proliferative fraction, and survival in resected cancer of the pancreas. Am J Surg (2003) 1.07
Demographic, clinical, and quality of life variables related to embarrassment in veterans living with an intestinal stoma. J Wound Ostomy Continence Nurs (2007) 1.05
Intraductal papillary mucinous neoplasm--when to resect? Adv Surg (2008) 1.05
Coping and acceptance: the greatest challenge for veterans with intestinal stomas. J Psychosom Res (2009) 1.04
Secretin-enhanced MR cholangiopancreatography: spectrum of findings. Radiographics (2013) 1.04
Solid pseudopapillary neoplasms of the pancreas: a multi-institutional study of 21 patients. J Surg Res (2009) 1.04
The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. Neoplasia (2006) 1.01
Role of 14-3-3σ in poor prognosis and in radiation and drug resistance of human pancreatic cancers. BMC Cancer (2010) 1.01
Cryoablation of unresectable pancreatic cancer. Surgery (2002) 1.01
The VA Ostomy Health-Related Quality of Life Study: objectives, methods, and patient sample. Curr Med Res Opin (2006) 1.00
Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Mol Cancer Ther (2007) 0.97
Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901 decreases hepatocellular carcinoma growth in vitro and in mouse model systems. Hepatology (2010) 0.97
Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma. HPB (Oxford) (2010) 0.97
International Consensus Guidelines parameters for the prediction of malignancy in intraductal papillary mucinous neoplasm are not properly weighted and are not cumulative. HPB (Oxford) (2014) 0.95
Influence of intestinal stoma on spiritual quality of life of U.S. veterans. J Holist Nurs (2008) 0.95
Pancreatic surgery: evolution at a high-volume center. Surgery (2010) 0.94
Adjuvant chemoradiation therapy for pancreatic adenocarcinoma: who really benefits? J Am Coll Surg (2009) 0.94
Glycomic and proteomic profiling of pancreatic cyst fluids identifies hyperfucosylated lactosamines on the N-linked glycans of overexpressed glycoproteins. Mol Cell Proteomics (2012) 0.94
Practical challenges in the secondary use of real-world data: the notifiable condition detector. AMIA Annu Symp Proc (2011) 0.94
Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia. Neoplasia (2006) 0.94
Outcomes of primary surveillance for intraductal papillary mucinous neoplasm. J Gastrointest Surg (2011) 0.93
Outcomes after preoperative endoscopic ultrasonography and biopsy in patients undergoing distal pancreatectomy. Surgery (2011) 0.93
A mixed-methods evaluation of health-related quality of life for male veterans with and without intestinal stomas. Dis Colon Rectum (2007) 0.93
IPMN-controversies in an "epidemic". J Surg Oncol (2006) 0.92
Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. HPB (Oxford) (2010) 0.92
Splenic preserving distal pancreatectomy: does vessel preservation matter? J Am Coll Surg (2011) 0.92
Consistency in the safety labeling of bioequivalent medications. Pharmacoepidemiol Drug Saf (2012) 0.91
Effect of celecoxib and the novel anti-cancer agent, dimethylamino-parthenolide, in a developmental model of pancreatic cancer. Pancreas (2008) 0.90
MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac. Pancreas (2003) 0.90
Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther (2009) 0.90
Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol (2011) 0.90
Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies. J Gastrointest Surg (2007) 0.89
Does the interval from imaging to operation affect the rate of unanticipated metastasis encountered during operation for pancreatic adenocarcinoma? Surgery (2011) 0.89
Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. HPB (Oxford) (2011) 0.88
A pilot study of proteomic profiles of human hepatocellular carcinoma in the United States. J Surg Res (2008) 0.88
Side-branch intraductal papillary mucinous neoplasms of the pancreatic head/uncinate: resection or enucleation? HPB (Oxford) (2011) 0.88
Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest. Mol Cancer Res (2006) 0.88
The natural history of main duct-involved, mixed-type intraductal papillary mucinous neoplasm: parameters predictive of progression. Ann Surg (2014) 0.88
Reducing surgical site infections in hepatopancreatobiliary surgery. HPB (Oxford) (2012) 0.87
Positive correlation of employment and psychological well-being for veterans with major abdominal surgery. Am J Surg (2010) 0.85
Ethanol-TGFalpha-MEK signaling promotes growth of human hepatocellular carcinoma. J Surg Res (2008) 0.85
Alcohol induces liver neoplasia in a novel alcohol-preferring rat model. Alcohol Clin Exp Res (2011) 0.85
Obesity increases malignant risk in patients with branch-duct intraductal papillary mucinous neoplasm. Surgery (2013) 0.85
The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC. J Surg Res (2008) 0.84
The proteome of normal pancreatic juice. Pancreas (2012) 0.84
Fluid analysis prior to surgical resection of suspected mucinous pancreatic cysts. A single centre experience. J Gastrointest Oncol (2011) 0.84
Comparison of computational algorithms for the classification of liver cancer using SELDI mass spectrometry: a case study. Cancer Inform (2007) 0.84
Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice. J Gastrointest Surg (2007) 0.84
Pancreatic necrosectomy: North American mortality is much lower than expected. J Am Coll Surg (2009) 0.84
Comorbidities play a larger role in predicting health-related quality of life compared to having an ostomy. Am J Surg (2007) 0.83
Survival after resection for invasive intraductal papillary mucinous neoplasm and for pancreatic adenocarcinoma: a multi-institutional comparison according to American Joint Committee on Cancer Stage. J Am Coll Surg (2011) 0.82
Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126. J Pediatr Surg (2006) 0.82
A comparison of automated methicillin-resistant Staphylococcus aureus identification with current infection control practice. AMIA Annu Symp Proc (2009) 0.80
Tailored α-methylene-γ-butyrolactones and their effects on growth suppression in pancreatic carcinoma cells. Bioorg Med Chem Lett (2010) 0.80
Postbrushing and fine-needle aspiration biopsy follow-up and treatment options for patients with pancreatobiliary lesions: the Papanicolaou Society of Cytopathology guidelines. Diagn Cytopathol (2014) 0.80
Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells. J Gastrointest Surg (2012) 0.80
Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer (2013) 0.80
Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer. J Surg Res (2007) 0.79